Impact Factor 6.244 | CiteScore 3.9
More on impact ›
Submit your manuscript
Scope
Cancer Immunity and Immunotherapy welcomes submissions on tumor immunity in animal models and in human cancers and aims at driving the rapidly moving field of immunosurveillance, tumor escape, and immunotherapy by hosting primary research, discussions, reviews, conflicting positions, and novel hypotheses.
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section.
Scope
Dramatic progresses have been made in the field of cancer immunity and immunotherapy during the preceding 15 years.
The clinical impact associated with the tumor immune infiltrate, the impressive clinical activities of monoclonal antibodies modulating the immune microenvironment or directed to tumor cells, the successes of engineered T cells therapies and the development of cancer vaccines against mutated tumor antigens demonstrate that the immune system can be a powerful ally against cancer.
The section’s ambitions are to drive the rapidly moving field of immunosurveillance, tumor escape and immunotherapy by hosting primary research, discussions, reviews, conflicting positions and novel hypotheses.
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section.
Indexed in: Chemical Abstracts Service (CAS), CLOCKSS, CrossRef, DOAJ, Google Scholar, PubMed, PubMed Central (PMC), Scopus, Web of Science Science Citation Index Expanded (SCIE)
PMCID: all published articles receive a PMCID
Cancer Immunity and Immunotherapy welcomes submissions of the following article types: Case Report, Classification, Clinical Trial, Correction, Editorial, Erratum, General Commentary, Hypothesis and Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Review, Systematic Review and Technology and Code.
All manuscripts must be submitted directly to the section Cancer Immunity and Immunotherapy, where they are peer-reviewed by the Associate and Review Editors of the specialty section.
Frontiers Editorial Office
Avenue du Tribunal Fédéral 34
CH – 1005 Lausanne
Switzerland
Tel +41 (0)21 510 17 00
Fax +41 (0)21 510 17 01
Frontiers Support
Tel +41 (0)21 510 17 10
Fax +41 (0)21 510 17 01
support@frontiersin.org
There are no results to display.
Click on any of the keywords to find further editors related to it.
- Article(s) found
- Latest
- Most viewed
This section has no articles.
There are no articles to display. Please try changing the filters.
- Research Topic(s) found
- Latest
- Most viewed
Contact Editorial Office
Avenue du Tribunal Fédéral 34
CH – 1005 Lausanne
Switzerland
Tel +41(0)21 510 17 40
Fax +41 (0)21 510 17 01
For all queries regarding manuscripts in Review and potential conflicts of interest, please contact oncology.editorial.office@frontiersin.org
For queries regarding Research Topics, Editorial Board applications, and journal development, please contact oncology@frontiersin.org
Tel +41(0)21 510 17 10
Fax +41 (0)21 510 17 01
For technical issues, please visit our Frontiers Help Center, or contact our IT HelpDesk team at support@frontiersin.org